Ligand Pharmaceuticals Inc (LGND)
70.37
-0.63
(-0.89%)
USD |
NASDAQ |
Apr 25, 16:00
70.26
-0.11
(-0.16%)
After-Hours: 20:00
Ligand Pharmaceuticals Accounts Payable (Quarterly): 2.427M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.427M |
September 30, 2023 | 2.475M |
June 30, 2023 | 9.582M |
March 31, 2023 | 6.135M |
December 31, 2022 | 5.307M |
September 30, 2022 | 15.89M |
June 30, 2022 | 19.15M |
March 31, 2022 | 6.972M |
December 31, 2021 | 8.403M |
September 30, 2021 | 7.233M |
June 30, 2021 | 17.27M |
March 31, 2021 | 9.469M |
December 31, 2020 | 3.784M |
September 30, 2020 | 10.17M |
June 30, 2020 | 6.103M |
March 31, 2020 | 3.365M |
December 31, 2019 | 2.42M |
September 30, 2019 | 2.04M |
June 30, 2019 | 2.888M |
March 31, 2019 | 5.061M |
December 31, 2018 | 4.183M |
September 30, 2018 | 1.647M |
June 30, 2018 | 2.682M |
March 31, 2018 | 3.407M |
December 31, 2017 | 2.259M |
Date | Value |
---|---|
September 30, 2017 | 3.617M |
June 30, 2017 | 1.799M |
March 31, 2017 | 6.456M |
December 31, 2016 | 2.734M |
September 30, 2016 | 2.757M |
June 30, 2016 | 2.336M |
March 31, 2016 | 2.688M |
December 31, 2015 | 4.083M |
September 30, 2015 | 3.143M |
June 30, 2015 | 2.708M |
March 31, 2015 | 7.442M |
December 31, 2014 | 7.698M |
September 30, 2014 | 4.864M |
June 30, 2014 | 5.059M |
March 31, 2014 | 3.675M |
December 31, 2013 | 3.951M |
September 30, 2013 | 4.304M |
June 30, 2013 | 4.755M |
March 31, 2013 | 5.522M |
December 31, 2012 | 5.854M |
September 30, 2012 | 6.027M |
June 30, 2012 | 6.746M |
March 31, 2012 | 7.893M |
December 31, 2011 | 11.06M |
September 30, 2011 | 10.07M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
2.04M
Minimum
Sep 2019
19.15M
Maximum
Jun 2022
7.426M
Average
6.135M
Median
Mar 2023
Accounts Payable (Quarterly) Benchmarks
ANI Pharmaceuticals Inc | 36.68M |
ADMA Biologics Inc | 15.66M |
Viking Therapeutics Inc | 5.225M |
Corcept Therapeutics Inc | 17.40M |
Palatin Technologies Inc | 1.594M |